Pfizer/BioNTech's new crown vaccine is likely to be approved in the UK this week

The new crown vaccine, developed by Pfizer and BioNTech, could be approved by UK regulators as early as this weekend.
clinicians have been told to prepare for the vaccine on December 1.
Government sources told the Daily Telegraph that a decision could be made within a week of the "best case scenario" and that the NHS might be ready to start distributing the vaccine by 1 December, according to British media reports.
this will mean that the Pfizer/BioNTech vaccine will be approved in the UK before the US.
November 18, Pfizer and BioNTech announced the final results of their Phase 3 clinical trial of BNT162b2, a candidate for the new crown vaccine based on mRNA technology, with a vaccine effectiveness of 95% (p<0.0001) in a group of subjects who had no new coronavirus infection in the past.
vaccine is consistent among age, gender, ethnic and ethnic groups, and more than 94 per cent of people over 65 years of age are observed to be effective.
analysis of safety data from 8,000 subjects over the age of 18 showed good vaccine tolerance, with most adverse events subsiding shortly after vaccination.
level 3 adverse events with a rate of more than 2% were fatigue (3.8%) and headache (2.0%), both after the second vaccination.
, older adults tend to report fewer and lighter adverse events, consistent with earlier results.
, Pfizer and BioNTech announced that they had filed an application with the FDA for emergency authorization (EUA) for the vaccine BNT162b2, or would be the first to be approved for use in the United States.
time, the British government's decision to approve within a week clearly preempted the vaccine, and the number of vaccines currently produced is still very limited relative to the population of each country.
the UK, the Medicines and Healthcare Products Regulatory Agency is an independent body that oversees the approval process and timing.
Health Minister Matt Hancock has formally asked the agency to review and approve Pfizer's vaccine.
reported that all safety and ability data will be sent to the UK Medicines and Healthcare Products Authority on Monday or Tuesday.
meeting of the FDA's EUA application for BNT162b2 will not take place until December 10.
, who heads the U.S. vaccine program, told CNN that the vaccine could be available "a day or two after approval, on December 11 or 12."
the same time, the NHS has a programme to vaccinate from 1 December and hopes that every adult in England will be vaccinated against Covid-19 by April next year.
nhs staff and seniors will first arrange vaccinations and roll them out further in the new year, according to the timetable for nursing home residents and health workers.
, however, the timing still depends on licensing and the punctuality of millions of vaccine products.
original schedule, drawn up a week ago, has been revised based on the latest information from manufacturers Pfizer and BioNTech.
Hancock said on Friday that he was becoming more confident that "life will be closer to normal next spring."
Jonathan Van Tam, deputy director-general of the Department of Health, said the NHS intended to "act as quickly as possible" and that vaccinations between priority groups would only be a few weeks away.
uk is currently recruiting up to 30,000 volunteers to manage Pfizer's vaccines.
about 28 million doses of the vaccine will be distributed at 40-50 "mass vaccination centres" in the UK, which will be located in conference centres, stadiums and other venues across the country.
nhs plans, an additional 34 million doses of the vaccine will be administered from 1,000 mass vaccination points managed by GHFs.
Pfizer's vaccine requires two doses, 28 days apart.
said it would deliver 10m of the 40m doses ordered in the UK by the end of the year.
the results of trials developed in collaboration with Oxford University and AstraZeneta will soon be available, making the vaccine easier to store, but has now resumed after clinical studies were suspended due to severe adverse reactions in previously involved patients.
source: 1.Pfizer COVID-19 vaccine can get UK this approval week 2.Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacys 3.SHOT IN ARM Pfizer vaccine can get go-ahead from UK regulatory inside a week